In a first for the neurotoxin market, Ipsen announced Thursday that its Dysport has hit the goals in two phase 3 trials for ...

The company claims that Dysport is now the first botulinum toxin therapy to demonstrate efficacy in episodic migraine.

Dysport® achieved statistically significant topline Phase III results, meeting primary endpoints in both episodic (E-BEOND) and chronic (C-BEOND) ...

The DIRECTION trial results show the safety profile for Dysport® (abobotulinumtoxinA) was non-inferior to Botox® (onabotulinumtoxinA) in adult patients with upper limb spasticity Patients treated with ...

Ipsen Biopharmaceuticals, an affiliate of Ipsen, announced today that the United States Food and Drug Administration has approved the expanded use of Dysport ® in pediatric patients. “The proactive ...

Ipsen IPN reported strong second-quarter results highlighted by total revenue of EUR 795 million, representing nearly 7% growth from the prior-year period. Strong revenue contributions from Dysport ...

Submission based on data from the pivotal international Phase III CONTENT clinical program, also recently published in European Urology1 CONTENT showed that Dysport® decreased incontinence episodes, ...

Approved as an anti-wrinkle treatment Approved to treat cervical dystonia Ipsen to launch Dysport for cervical dystonia in H2 Medicis to launch Dysport for aesthetic use in 30-60 days Ipsen shares up ...

Ipsen IPN reported solid third-quarter results highlighted by total revenue of EUR 772 million, representing 6.5% growth from the prior-year period at constant exchange rates. Strong sales from ...

Ipsen (Euronext: IPN; ADR: IPSEY) today announced that Dysport® (abobotulinumtoxinA) has received positive opinion in Europe for the management of urinary incontinence (UI) in adults with neurogenic ...

PARIS, FRANCE – 19 MAY 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today results from the only prospective, head-to-head Phase IV DIRECTION trial comparing Dysport ® (abobotulinumtoxinA) to ...